Format

Send to

Choose Destination
Eur Respir Rev. 2019 Jun 26;28(152). pii: 190002. doi: 10.1183/16000617.0002-2019. Print 2019 Jun 30.

Breath analysis of cancer in the present and the future.

Author information

1
Dept of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion - Israel Institute of Technology, Haifa, Israel.
2
Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
3
University of Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
4
Dept of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion - Israel Institute of Technology, Haifa, Israel hhossam@technion.ac.il.

Abstract

Most of the currently used diagnostics for cancerous diseases have yet to meet the standards of screening, as they are insufficiently accurate and/or invasive and risky. In this review, we describe the rationale, the progress made to date, and the potential of analysing the exhaled volatile organic compounds as a pathway for enabling early diagnosis of cancer and, therefore, for achieving better clinical prognosis and survival rates. The review highlights the major advancements made in this field, from fundamentals, up to translational phases and clinical trials, with a special emphasis on sensing platforms based on nanomaterials. The prospects for breath analysis in early cancerous disease are presented and discussed.

PMID:
31243094
DOI:
10.1183/16000617.0002-2019
Free full text

Conflict of interest statement

Conflict of interest: R. Einoch Amor has nothing to disclose. Conflict of interest: M.K. Nakhleh has nothing to disclose. Conflict of interest: O. Barash has nothing to disclose. Conflict of interest: H. Haick has nothing to disclose.

Publication type

Publication type

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center